SCHEMBL17153242

SCHEMBL17153242

CN(CCCN(C)c1ncc(-c2ccnc(Nc3cccc(CO[Si](C)(C)C(C)(C)C)c3)n2)cn1)C(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK19 Q9BWU1 2/20 0.39
CDC7 O00311 1/20 0.39
ABL1 P00519 13/20 0.38
BCR P11274 11/20 0.38
SRC P12931 4/20 0.38
PRKCA P17252 4/20 0.37
PDGFRB P09619 4/20 0.37
PDGFRA P16234 4/20 0.37
PRKCD Q05655 2/20 0.37
JAK2 O60674 2/20 0.36
FLT3 P36888 1/20 0.36
CCNT1 O60563 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
CCNA1 P78396 1/20 0.36
PLK1 P53350 1/20 0.35
EGFR P00533 3/20 0.35
ERBB2 P04626 1/20 0.35
IGF1R P08069 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17153127 0.90 CDC7 (0.41) CDK19CDC7ABL1BCRSRC
SCHEMBL17153126 0.89 CDC7 (0.41) CDK19CDC7ABL1BCRSRC
SCHEMBL17152832 0.83 JAK2 (0.45) CDK19CDC7ABL1BCRSRC
SCHEMBL17153054 0.81 CDK19 (0.43) CDK19CDC7ABL1BCRSRC
SCHEMBL17153086 0.81 JAK2 (0.40) CDK19CDC7ABL1BCRSRC
SCHEMBL17154924 0.80 BUB1 (0.38)
SCHEMBL17153041 0.79 CDK19 (0.41) CDK19CDC7ABL1BCRSRC
SCHEMBL17152801 0.77 CDC7 (0.43) CDK19CDC7ABL1BCRSRC
SCHEMBL17152843 0.77 PRKCA (0.42) CDK19CDC7ABL1BCRSRC
SCHEMBL17152838 0.77 CCNT1 (0.37) CDK19CDC7ABL1BCRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-01-26 US disclosed
WO-2015150555-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022202-A1 MACROCYLIC PYRIMIDINE DERIVATIVES EEF2K, VPS26B, VPS28 CDK19 979/4885CDC7 1539/4885ABL1 3037/4885
US-10017509-B2 Macrocylic pyrimidine derivatives EEF2K, VPS26B, VPS28 CDK19 979/4885CDC7 1539/4885ABL1 3037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.